Dec 30, 2025 • Finviz
SOMEWHAT-BULLISH
2 Growth Stocks to Buy For 2026 and Beyond
This article recommends Vertex Pharmaceuticals (NASDAQ: VRTX) and DexCom (NASDAQ: DXCM) as two growth stocks to consider for 2026 and beyond. Vertex faces setbacks but has promising pipeline candidates and recent product launches like Journavx, while DexCom, a leader in continuous glucose monitoring (CGM), is expanding its market despite some product recalls and concerns about new diabetes treatments. Both companies are positioned for long-term growth through new product launches and market expansion.
Dec 30, 2025 • TradingView — Track All Markets
BULLISH
3 Stocks Likely to Gain From Rising HSA Contribution & Medicare Premium
The article discusses how rising Health Savings Account (HSA) contribution limits and increased Medicare premiums in 2026 are expected to impact healthcare financing and medical device demand. It highlights three companies—DexCom (DXCM), ResMed (RMD), and Masimo (MASI)—that are well-positioned to benefit from these shifts due to their focus on chronic disease management and cost-effective medical technologies. The changes could encourage greater adoption of devices that reduce long-term healthcare costs and improve patient outcomes.
Dec 30, 2025 • ts2.tech
NEUTRAL
Medtronic stock slips as year-end trading thins and Fed minutes loom
Medtronic shares closed down 0.4% at $96.15 as year-end trading thins, with investors de-risking and awaiting fresh clues on interest rates from upcoming Federal Reserve minutes. The medical-device maker's decline is attributed to macro positioning rather than company-specific news, though its diabetes business, MiniMed, has filed for an IPO. Investors are also looking ahead to Medtronic's fiscal Q3 2026 earnings report on February 17.
Dec 27, 2025 • MarketBeat
BULLISH
SWS Partners Purchases 19,073 Shares of DexCom, Inc. $DXCM
SWS Partners increased its stake in DexCom, Inc. (NASDAQ:DXCM) by 100.2% in the third quarter, acquiring an additional 19,073 shares to hold a total of 38,102 shares valued at approximately $2.56 million. DexCom recently surpassed Q3 earnings estimates with EPS of $0.61 and revenue of $1.21 billion, leading analysts to project roughly $2.03 EPS for the current year. The stock currently holds a "Moderate Buy" rating with an average price target of $86.61, and institutional ownership remains high at 97.75%.
Dec 27, 2025 • MyStateline
BEARISH
Recover Investment Losses: Class Action Initiated Against DexCom, Inc. (DXCM)
A securities class action lawsuit has been filed against DexCom, Inc. (NASDAQ:DXCM) on behalf of investors who purchased securities between January 8, 2024, and September 17, 2025. The lawsuit alleges that DexCom made false statements and concealed material design changes to its glucose monitoring products, the G6 and G7, that were unauthorized by the FDA and rendered the devices less reliable, posing health risks to users. Levi & Korsinsky, LLP is representing the investors seeking to recover losses due to alleged securities fraud.
Dec 27, 2025 • MarketBeat
SOMEWHAT-BULLISH
Exchange Traded Concepts LLC Acquires New Shares in Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp $SBS
Exchange Traded Concepts LLC recently acquired 69,531 shares of Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp (NYSE:SBS) for approximately $1.73 million, establishing a new position in Q3. The utilities provider reported Q3 EPS of $0.34, significantly beating analyst estimates of $0.07, and revenues of $4.69 billion. SABESP also announced a 1.02964697 stock split effective December 29th and a special dividend of $0.4772 payable on May 11th.